Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by Xijing Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Fourth Military Medical University
Xi’an Jiaotong University College of Medicine
Information provided by:
Xijing Hospital
ClinicalTrials.gov Identifier:
NCT01201655
First received: September 13, 2010
Last updated: NA
Last verified: January 2010
History: No changes posted
  Purpose

The purpose of this study is to investigate the impact of splenectomy coupled with portal-azygous disconnection on hepatocarcinogenesis in patients with post-hepatitic cirrhosis after hepatitis B or C virus infection by retrospective case-control study,We hope to find a new idear and method to prevent or cure HCC.


Condition
Liver Cirrhosis
Carcinoma, Hepatocellular
Splenomegaly
Laparotomy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Multicentric Retrospective Case Control Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis

Resource links provided by NLM:


Further study details as provided by Xijing Hospital:

Estimated Enrollment: 5000
Study Start Date: January 2010
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Detailed Description:

A case-control study was carried out. The factors studied include age, gender, ascites, hepatic encephalopathy, ALT, AST, TBIL, ALP, GGT, Child-Pugh classification of liver function, and history of splenectomy with portal-azygous disconnection during the treatment of portal hypertension. According to the Child-Pugh classification, these cases were graded as A, B, and C. And according to the ranges of the normal reference values of the data, they were categorized into two groups including a normal group and an abnormal group.The data mainly comes from FMMU and Xi'an jiaotong university from the year of 2002 to 2012.

  Eligibility

Ages Eligible for Study:   20 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

post-hepatitic cirrhosis with portal hypertension and hypersplenism patients

Criteria

Inclusion Criteria:

  • after surgery

Exclusion Criteria:

  • without surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01201655

Contacts
Contact: Chen yong, professor 13891915509 cheny@fmmu.edu.cn

Locations
China, Shaanxi
Chen yong Recruiting
Xi'an, Shaanxi, China, 710032
Contact: Chen yong, professor    13891915509    cheny@fmmu.edu.cn   
Sub-Investigator: Li zhe, professor         
Sponsors and Collaborators
Xijing Hospital
Fourth Military Medical University
Xi’an Jiaotong University College of Medicine
Investigators
Study Director: Chen yong, professor Xia jielai
  More Information

No publications provided

Responsible Party: chen yong, Xijing Hospital
ClinicalTrials.gov Identifier: NCT01201655     History of Changes
Other Study ID Numbers: chenyong
Study First Received: September 13, 2010
Last Updated: September 13, 2010
Health Authority: China: Food and Drug Administration

Keywords provided by Xijing Hospital:
Posthepatitic cirrhosis;
Hepatocarcinogenesis;
Splenectomy;

Additional relevant MeSH terms:
Splenomegaly
Carcinoma, Hepatocellular
Hypersplenism
Liver Cirrhosis
Adenocarcinoma
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Hypertrophy
Liver Diseases
Liver Neoplasms
Lymphatic Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Pathological Conditions, Anatomical
Splenic Diseases

ClinicalTrials.gov processed this record on November 24, 2014